Filing Analysis
Dyadic International, Inc. entered into a registered direct offering and a concurrent private placement of warrants to raise approximately $2.9 million in gross proceeds. The offering involves the issuance of 3,625,000 common shares at $0.795 per share and 3,625,000 warrants with an exercise price of $0.84 per share.
🚩 Red Flags
- Significant dilution: Issuance of 3.625M new shares plus 3.625M warrants (potential for further dilution upon exercise).
- Low share price: Offering price of $0.795 is near the penny stock threshold, often indicative of liquidity needs.
- Small capital raise: Total gross proceeds of $2.9 million are relatively small, suggesting a need for frequent capital infusions.
📋 Key Facts
- Registered Offering: 3,625,000 shares of common stock at $0.795 per share.
- Concurrent Private Placement: 3,625,000 warrants with an exercise price of $0.84 per share.
- Expected aggregate gross proceeds: Approximately $2.9 million (before expenses).
- Closing expected on or about August 14, 2026.
- Placement Agent: Aegis Capital Corp.
- Standstill restrictions: 90-day restriction on issuance/sale of shares and a 90-day lock-up for directors, officers, employees, and 10%+ shareholders.
Dyadic International, Inc. filed an 8-K to announce its quarterly results for the period ending June 30, 2026. The filing serves as a formal notice that a press release containing financial performance data has been issued.
📋 Key Facts
- Report date: August 12, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes Exhibit 99.1, which is the official press release regarding results of operations and financial condition.
Dyadic International, Inc. announced that Nasdaq has confirmed the company has regained compliance with minimum bid price requirements (Rules 5550(a)(2) and 5550(b)). The common stock will continue to be listed on the Nasdaq Capital Market.
🚩 Red Flags
- Historical delisting risk: The filing implies a recent period of non-compliance with minimum bid price requirements (Rule 5550).
📋 Key Facts
- Nasdaq confirmed compliance with Listing Rules 5550(a)(2) and 5550(b).
- The company's common stock (DYAI) remains listed on the Nasdaq Capital Market.
- Compliance was officially confirmed as of July 24, 2026.
Dyadic International, Inc. held its 2026 Annual Meeting of Shareholders on June 18, 2026. The most significant outcome was the approval of a proposal to authorize the board to effect a reverse stock split at their discretion.
🚩 Red Flags
- Approval of a reverse stock split (typically used to boost share price to meet exchange listing requirements or avoid delisting).
- High number of 'Broker Non-Votes' in director elections and compensation votes suggests significant shareholder passivity or inability to vote certain shares.
📋 Key Facts
- Annual Meeting held on June 18, 2026.
- Proposal 2 (Reverse Stock Split authorization) passed with 25,419,068 votes 'For'.
- Dr. Seth J. Herbst was elected to the Board of Directors (Class I).
- Crowe LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2026.
- Advisory vote on executive compensation was approved.
Dyadic International received notification from Nasdaq that it has initiated delisting proceedings due to failures to meet the minimum bid price of $1.00 and continued listing standards. The company intends to request a hearing to stay the delisting and seek an extension to regain compliance.
🚩 Red Flags
- Multiple listing rule violations (Bid Price and Continued Listing Standards).
- Lack of sufficient shareholders' equity ($< $5M) to automatically qualify for a bid price extension.
- Explicit reference to the risk of being unable to 'continue to operate as a going concern' if delisted.
📋 Key Facts
- Received delisting notification from Nasdaq on June 18, 2026.
- Failed to maintain minimum bid price of $1.00 per share (Rule 5450(a)(1)).
- Failed to meet the $5 million shareholders' equity requirement for a bid price extension.
- Failed to meet Continued Listing Standards (Rule 5550(b)), which requires $2.5M equity, $35M market value, or $500k net income.
- Company plans to request a hearing before an independent Nasdaq panel to stay the delisting.
- Maximum compliance extension possible through December 15, 2026.
Dyadic International, Inc. issued a press release on June 15, 2026, highlighting increased interest in its C1 Biomanufacturing Platform, specifically citing Ebola preparedness activities and growing commercial adoption.
📋 Key Facts
- The company issued a press release titled 'Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption'.
- The filing date is June 15, 2026.
- The information was furnished under Item 7.01 (Regulation FD Disclosure), meaning it is not officially 'filed' for Section 18 liability purposes.
Dyadic International, Inc. announced a collaboration with Scripps Research to develop rapid-response Hantavirus antibodies and vaccines, leveraging Dyadic's C1 platform and prior research on Andes, Marburg, and Ebola viruses.
📋 Key Facts
- Collaboration partner: Scripps Research
- Focus: Rapid-response Hantavirus antibody and vaccine development
- Technology used: Dyadic's C1 Platform for biologic production
- Date of announcement: May 28, 2026
Dyadic International, Inc. (DYAI) announced its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished under Item 2.02 of Form 8-K.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The press release was issued on May 13, 2026.
- The report was signed by CEO Mark A. Emalfarb.
- The information is furnished under Item 2.02 and is not deemed 'filed' for Section 18 purposes.
Dyadic International received a Nasdaq deficiency notice on March 27, 2026, for failing to meet the minimum stockholders' equity, market value, or net income requirements. This represents a second active listing deficiency for the company, which is already non-compliant with the $1.00 minimum bid price rule.
🚩 Red Flags
- Multiple concurrent Nasdaq listing deficiencies (financial standards and bid price).
- Stock price is below the $1.00 minimum requirement.
- Failure to meet any of the three alternative financial requirements for continued listing.
- Risk of delisting if compliance plans are not accepted or executed successfully.
📋 Key Facts
- Received Nasdaq deficiency notice on March 27, 2026, regarding Rule 5550(b).
- Company failed to maintain $2.5 million in stockholders' equity, $35 million in market value, or $500,000 in net income.
- The company has 45 calendar days (until May 11, 2026) to submit a plan to regain compliance.
- A separate deficiency regarding the $1.00 minimum bid price (Rule 5550(a)(2)) is already active with a June 17, 2026 deadline.
- If a compliance plan is accepted, the company may receive a cure period until September 23, 2026.
Dyadic International, Inc. announced its financial results for the full fiscal year ended December 31, 2025, via a press release on March 25, 2026.
📋 Key Facts
- The filing reports financial results for the fiscal year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was included as Exhibit 99.1.
- The report was signed by CEO Mark A. Emalfarb on March 25, 2026.
Dyadic International, Inc. entered into an At-The-Market (ATM) Issuance Sales Agreement with Craig-Hallum Capital Group LLC to sell up to $4,237,818 of its common stock. The sales will be made from time to time at prevailing market prices to provide the company with flexible access to capital.
🚩 Red Flags
- Potential dilution of existing shareholders as shares are sold into the open market.
📋 Key Facts
- Entered into an ATM Sales Agreement with Craig-Hallum Capital Group LLC on March 6, 2026.
- The company may sell shares of common stock with an aggregate offering price of up to $4,237,818.
- Sales agent will receive a commission of up to 3.0% of gross sales proceeds.
- The offering is conducted under an existing Form S-3 registration statement (File No. 333-273829) effective since August 25, 2023.
Dyadic International, Inc. has amended its Senior Secured Convertible Promissory Notes due March 2027. The amendment extends the maturity date to December 31, 2027, and sets a conversion price of $1.05 per share.
🚩 Red Flags
- Convertible debt with a fixed conversion price often leads to significant dilution for existing shareholders.
- Extension of maturity suggests the company is seeking more time to meet obligations or improve liquidity before repayment becomes due.
- The removal of redemption rights in favor of noteholders shifts control/leverage toward the lenders.
📋 Key Facts
- Maturity Date extended from March 8, 2027, to December 31, 2027.
- Conversion price set at $1.05 per share of common stock.
- Amendment removes the holders' right to elect Company redemption (except in Event of Default).
- The notes are Senior Secured Convertible Promissory Notes.
Dyadic International, Inc. received a deficiency notice from Nasdaq because its stock price has fallen below the $1 minimum bid requirement for 30 consecutive business days. The company has until June 17, 2026, to regain compliance through a 180-day grace period.
🚩 Red Flags
- Delisting notice from Nasdaq (Item 3.01).
- Failure to maintain minimum bid price requirement.
- Historical net losses mentioned in forward-looking statements risk factors.
- Potential for delisting if compliance is not achieved by the deadline.
📋 Key Facts
- Received deficiency notice from Nasdaq on December 19, 2025.
- Violation of Nasdaq Listing Rule 5550(a)(2) regarding the $1 minimum bid price requirement.
- Compliance deadline (Compliance Date) is June 17, 2026.
- The company must achieve a closing bid price of at least $1.00 for 10 consecutive business days to regain compliance.
- A second 180-day extension may be available if market value requirements are met and the company provides notice of intent to cure.
Dyadic International, Inc. filed an 8-K to announce its quarterly earnings results for the period ending September 30, 2025. The filing serves as a formal notice that a press release containing these financial results has been issued.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes Exhibit 99.1, which is the official press release containing financial results.
- Information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Dyadic International, Inc. has successfully regained compliance with Nasdaq listing requirements regarding minimum market value and minimum bid price. The company resolved two previous deficiency notices that threatened its continued listing on the Nasdaq Capital Market.
🚩 Red Flags
- Historical delisting risk: The company was facing imminent delisting due to both market value and share price deficiencies throughout mid-2025.
📋 Key Facts
- Regained compliance with Nasdaq Listing Rule 5550(b)(2) (minimum market value of $35M) as of October 1, 2025.
- Regained compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid price of $1.00) as of October 3, 2025.
- The market value requirement was met for the period between September 16, 2025 and September 30, 2025.
- The minimum bid price requirement was met for the period between September 19, 2025 and October 2, 2025.
Dyadic International entered into an amendment to its existing Security Agreement regarding Senior Secured Convertible Promissory Notes due in 2027. The amendment updates the list of secured parties to include a trust for the benefit of CEO Mark Emalfarb following his personal purchase and assignment of $1,000,000 in notes.
🚩 Red Flags
- Related-party transaction: The CEO has personally acquired a portion of the company's senior secured debt, creating potential conflicts of interest regarding creditor rights vs. shareholder interests.
- Debt structure complexity: The use of Senior Secured Convertible Promissory Notes often indicates significant dilution risk for existing shareholders.
📋 Key Facts
- Amendment to Security Agreement dated September 15, 2025.
- The amendment relates to Senior Secured Convertible Promissory Notes due March 8, 2027.
- CEO Mark Emalfarb purchased and was assigned $1,000,000 in principal amount of the notes via a trust.
- Schedule A of the Security Agreement was replaced to reflect updated Secured Parties.
Dyadic International, Inc. filed an 8-K to announce its quarterly earnings results for the period ended June 30, 2025. The filing serves as a formal notice that a press release containing these financial results has been issued.
📋 Key Facts
- Report date: August 13, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Information is furnished under Item 2.02 and not 'filed' for purposes of Section 18 liability.
Dyadic International, Inc. has completed a public offering of 6,052,000 shares of common stock at $0.95 per share to raise approximately $5.3 million in net proceeds for working capital and general corporate purposes.
🚩 Red Flags
- Significant dilution: Issuance of over 6 million shares at a low price point ($0.95) suggests substantial dilution for existing shareholders.
- Low share price: The offering price of $0.95 is near the threshold for Nasdaq minimum bid requirements, indicating potential liquidity or capital constraints.
📋 Key Facts
- Offered 6,052,000 shares of common stock.
- Public offering price: $0.95 per share.
- Expected net proceeds: approximately $5.3 million (after discounts and expenses).
- Underwriter: Craig-Hallum Capital Group LLC.
- Closing date for the offering: August 1, 2025.
- Use of proceeds: Working capital, product development, sales, and marketing.
Dyadic International, Inc. released a corporate presentation detailing its strategic shift from a research-centric organization to a commercially focused enterprise. The company is emphasizing the commercialization of its C1 and Dapibus™ gene expression platforms across life sciences, food, nutrition, and industrial bioprocessing sectors.
📋 Key Facts
- Company posted a presentation titled 'Precision engineered recombinant protein production that redefines performance, scalability and economy' on July 23, 2025.
- Strategic focus is shifting toward commercializing high-value, non-therapeutic proteins.
- Key technologies highlighted include the patented C1 and Dapibus™ gene expression platforms.
- Target sectors include life sciences, food, nutrition, and industrial bioprocessing.
Dyadic International, Inc. received a deficiency notice from Nasdaq for failing to maintain a minimum bid price of $1.00 per share over the last 30 consecutive business days. The company is also currently out of compliance with the Minimum Market Value of Listed Securities (MVLS) requirement.
🚩 Red Flags
- Delisting notice received for minimum bid price.
- Existing non-compliance with Minimum Market Value of Listed Securities (MVLS) requirement.
- Dual compliance deadlines: Dec 20, 2025 (MVLS) and Jan 13, 2026 (Bid Price).
- History of net losses mentioned in forward-looking statements risk factors.
📋 Key Facts
- Received Nasdaq deficiency notice on July 17, 2025, regarding minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- The company has until January 13, 2026, to regain compliance via a 180-day cure period.
- To cure the bid price deficiency, stock must close at $1.00 or more for at least 10 consecutive business days before the Compliance Date.
- The company is already out of compliance with the Minimum Market Value of Listed Securities (MVLS) requirement ($35 million).
- The deadline to cure the MVLS deficiency is December 20, 2025.
Dyadic International, Inc. announced a rebranding initiative where it will begin doing business as 'Dyadic Applied BioSolutions' effective in 30 days. The legal name of the entity remains unchanged.
📋 Key Facts
- Effective date for new trade name: Approximately August 1, 2025 (30 days from July 2, 2025).
- New trade name: 'Dyadic Applied BioSolutions'.
- Legal name remains: 'Dyadic International, Inc.'
- The announcement was made via press release under Item 7.01.
Dyadic International, Inc. received a deficiency notice from Nasdaq because its Market Value of Listed Securities (MVLS) fell below the required $35 million threshold for 30 consecutive business days. The company has until December 20, 2025, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5550(b)(2)).
- Potential risk of delisting if compliance is not met by December 20, 2025.
- Mention of historical net losses and capital needs in forward-looking statements.
📋 Key Facts
- Received deficiency notice on June 23, 2025.
- Failure to maintain minimum Market Value of Listed Securities (MVLS) of $35 million per Nasdaq Listing Rule 5550(b)(2).
- Compliance deadline is December 20, 2025.
- To regain compliance, MVLS must close at $35 million or more for at least 10 consecutive business days before the Compliance Date.
Dyadic International, Inc. reported the final voting results from its 2025 Annual Meeting of Shareholders held on June 20, 2025. The meeting included elections for Class III Directors and advisory votes regarding auditor ratification and executive compensation.
📋 Key Facts
- Annual Meeting held on June 20, 2025.
- Mark A Emalfarb was elected to the Board as a Class III Director (15,946,385 'For' votes).
- Crowe LLP was ratified as the Independent Registered Public Accounting Firm for fiscal year ending Dec 31, 2025.
- Shareholders voted in favor of an annual frequency for advisory votes on executive compensation (1-year cycle).
Dyadic International, Inc. announced the promotion of Joseph Hazelton to President, effective May 29, 2025. Mr. Hazelton will retain his current role as Chief Operating Officer while assuming the new presidency.
📋 Key Facts
- Joseph Hazelton appointed as President on May 29, 2025.
- Hazelton will continue to serve as Chief Operating Officer (COO).
- Base salary increased by approximately 10% to $320,000.
- Grant of 25,000 stock options with a ten-year term, vesting annually over four years.
- The Board also amended and restated the Company's Bylaws to modernize procedures for virtual meetings and stockholder lists.
Dyadic International, Inc. filed an 8-K to announce its quarterly results for the period ending March 31, 2025. The filing serves as a formal announcement of the earnings press release issued on May 14, 2025.
📋 Key Facts
- Report date: May 14, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
Dyadic International, Inc. entered into a Second Amendment to its existing Senior Secured Convertible Promissory Note due March 8, 2027. The amendment extends the Redemption Date for the notes to December 1, 2026.
🚩 Red Flags
- Modification of debt terms often indicates liquidity management or pressure from creditors/noteholders.
- Use of convertible notes can lead to significant future dilution for existing shareholders upon conversion.
📋 Key Facts
- The company entered into a Second Amendment to the Form of Senior Secured Convertible Promissory Note on May 1, 2025.
- The original maturity date for the Convertible Notes was March 8, 2027.
- The amendment shifts the Redemption Date to December 1, 2026.
- The agreement was entered into with a majority of current holders of the Convertible Notes.
Dyadic International, Inc. announced that Arindam Bose will retire from the Board of Directors effective at the company's annual meeting on June 20, 2025.
📋 Key Facts
- Arindam Bose notified the Board of his decision to retire as a director.
- Retirement is effective upon the company's annual meeting scheduled for June 20, 2025.
- Mr. Bose intends to continue serving on the Board until the specified retirement date.
- The departure is not due to any disagreement with the Company regarding operations, policies, or practices.
Dyadic International, Inc. issued an 8-K to announce its full-year financial results for the fiscal year ended December 31, 2024, and provided recent business updates via a press release.
📋 Key Facts
- Report date: March 26, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing includes an earnings press release as Exhibit 99.1
- Information is furnished under Item 2.02 and not considered 'filed' for liability purposes of Section 18.
Dyadic International, Inc. issued a press release regarding funding awards from the Coalition for Epidemic Preparedness and Innovations (CEPI). The funds are intended to accelerate the development of protein-based vaccines using the company's C1 platform.
📋 Key Facts
- Company received funding awards from CEPI on March 20, 2025.
- The purpose of the funding is to use the C1 platform to accelerate the development of protein-based vaccines.
- The announcement was made via a press release furnished as Exhibit 99.1.
Dyadic International, Inc. entered into a material grant agreement with the Bill & Melinda Gates Foundation on November 16, 2024. The agreement provides funding for cell line development of monoclonal antibodies targeting RSV and malaria using the company's proprietary C1 protein production platform.
📋 Key Facts
- Entered into an agreement with the Bill & Melinda Gates Foundation on November 16, 2024.
- Grant amount is $3,092,136.00.
- Purpose: Cell line development of monoclonal antibodies targeting respiratory syncytial virus (RSV) and malaria.
- Technology utilized: Proprietary C1 protein production platform.
Dyadic International, Inc. filed an 8-K to announce its quarterly earnings results for the period ending September 30, 2024.
📋 Key Facts
- The filing was made on November 12, 2024.
- The report pertains to the quarter ended September 30, 2024.
- Results were announced via a press release attached as Exhibit 99.1.
Dyadic International, Inc. announced the entry into a new employment agreement with Ping Rawson as Chief Financial Officer on November 8, 2024.
📋 Key Facts
- Ping Rawson entered into an employment agreement as CFO effective November 8, 2024.
- Annual base salary is set at $269,024.
- Target annual bonus of up to 25% of base salary, determined by a mix of company results (50%) and individual goals (50%).
- Bonus may be paid in cash or a combination of cash and equity (options/RSUs).
- Agreement includes a one-year post-termination non-competition provision.
- Agreement includes a two-year post-termination non-solicitation provision for employees, vendors, and customers.
Dyadic International, Inc. amended its existing Senior Secured Convertible Promissory Notes due March 8, 2027. The amendment modifies the conversion price and establishes specific redemption dates.
🚩 Red Flags
- Modification of conversion price in a convertible note can lead to significant dilution for existing shareholders if the stock price remains below or near the conversion price.
- The presence of senior secured convertible notes indicates ongoing debt management and potential liquidity pressures common in micro-cap companies.
📋 Key Facts
- Amendment to Form of Senior Secured Convertible Promissory Note due March 8, 2027.
- New conversion price set at $1.40 per share of common stock.
- Redemption Date will fall on the 26th, 29th, and 32nd month anniversaries of the original issue date.
Dyadic International, Inc. filed an 8-K to announce its quarterly earnings results for the period ending June 30, 2024.
📋 Key Facts
- The filing was made on August 13, 2024.
- The report pertains to the quarter ended June 30, 2024.
- Results were announced via a press release attached as Exhibit 99.1.
Dyadic International entered into a License and Development Agreement with Proliant Biologicals, LLC to license its proprietary fungal microbial expression platforms for the production of recombinant serum albumin. The deal includes upfront payments and profit-sharing components.
🚩 Red Flags
- The total fixed cash component ($1.5M) is relatively small for a micro-cap, suggesting the deal may be more about validation than immediate liquidity.
📋 Key Facts
- Agreement date: June 27, 2024
- Counterparty: Proliant Biologicals, LLC (dba Proliant Health and Biologicals)
- Upfront payment to Dyadic: $500,000
- Second milestone payment: $500,000 upon completion of Production Strain transfer
- Third milestone payment: $500,000 upon meeting a productivity threshold
- Dyadic to receive a share of profits from Proliant's sale of animal-free recombinant serum albumin products
Dyadic International entered into a License and Development Agreement with Proliant Biologicals, LLC to license its proprietary fungal microbial expression platforms for the production of recombinant serum albumin. The agreement includes upfront payments and profit-sharing components.
🚩 Red Flags
- The total fixed cash component ($1.5M) is relatively small for a micro-cap company, suggesting the deal may be more about platform validation than immediate significant liquidity.
📋 Key Facts
- Agreement date: June 27, 2024
- Counterparty: Proliant Biologicals, LLC (dba Proliant Health and Biologicals)
- Upfront payment to Dyadic: $500,000
- Second milestone payment: $500,000 upon completion of Production Strain transfer
- Third milestone payment: $500,000 upon meeting a specific productivity threshold
- Dyadic will receive a share of profits from Proliant's sale of animal-free recombinant serum albumin products.
Dyadic International, Inc. held its 2024 Annual Meeting of Shareholders on June 11, 2024. The filing reports the final voting results for director elections, auditor ratification, and executive compensation advisory votes.
📋 Key Facts
- Annual Meeting held on June 11, 2024.
- Class II Directors Jack L. Kaye and Patrick Lucy were elected to terms ending at the 2027 Annual Meeting.
- Crowe LLP was ratified as the Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2024, with 99.78% of votes cast in favor.
- Executive compensation advisory vote (Say-on-Pay) passed with 97.76% approval.
Dyadic International, Inc. issued an 8-K to announce its quarterly earnings results for the period ending March 31, 2024.
📋 Key Facts
- Report date: May 14, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing serves to furnish results of operations and financial condition via a press release (Exhibit 99.1).
Dyadic International announced several leadership changes, including the appointment of Patrick Lucy as Chairman and Joseph Hazelton as COO. Additionally, two directors, Michael Tarnok and Dr. Barry C. Buckland, have announced their intentions to retire in 2025 and 2024, respectively.
🚩 Red Flags
- Succession of multiple board members (Tarnok and Buckland) indicates upcoming turnover in governance structure.
📋 Key Facts
- Patrick Lucy appointed as Chairman of the Board, succeeding Michael Tarnok (effective March 26, 2024).
- Michael Tarnok to retire as a director at the annual meeting in June 2025; no disagreement with company reported.
- Dr. Barry C. Buckland to retire as a director at the annual meeting in June 2024; no disagreement with company reported.
- Joseph Hazelton (current Chief Business Officer) appointed as Chief Operating Officer, effective immediately.
- Company released full-year 2023 financial results via press release on March 28, 2024.
Dyadic International issued $6.0 million in 8.0% Senior Secured Convertible Promissory Notes to purchasers consisting of immediate family members and trusts related to the CEO, Mark Emalfarb. The notes are secured by a first-priority lien on substantially all company assets.
🚩 Red Flags
- Related-party transaction: Debt issued to the CEO's family members/trusts.
- High-security collateral: First-priority lien on substantially all company assets granted to insiders.
- Potential for significant dilution via convertible notes at $1.79 per share.
- Restrictive covenants in the security agreement regarding debt, dividends, and asset transactions.
📋 Key Facts
- Issued $6.0 million in 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027.
- Purchasers include immediate family members and family trusts related to CEO Mark Emalfarb (e.g., The Francisco Trust U/A/D February 28, 1996).
- Notes are secured by a first-priority lien on substantially all assets of the Company and its subsidiary, Dyadic International (USA), Inc.
- Initial conversion price set at $1.79 per share.
- Net proceeds estimated at approximately $5,850,000 for working capital and general corporate purposes.
- Default interest rate is 18% per annum upon acceleration of debt.